Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team.

Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.

2.

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. Erratum in: J Acquir Immune Defic Syndr 2000 Mar 1;23(3):278.

PMID:
10961606
3.

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM.

J Infect Dis. 2001 Jul 1;184(1):37-42. Epub 2001 May 30.

4.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.

N Engl J Med. 1999 Dec 16;341(25):1874-81.

5.

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C.

J Antimicrob Chemother. 2000 Mar;45(3):343-7.

6.

High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.

Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB.

AIDS. 1999 May 7;13(7):870-1. No abstract available.

PMID:
10357395
7.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

8.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, Spector SA.

Clin Pharmacol Ther. 2008 Feb;83(2):300-6. Epub 2007 Jul 4.

9.

Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group.

Pediatr Infect Dis J. 2002 Jul;21(7):659-63.

PMID:
12237599
10.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH; Adult AIDS Clinical Trials Group 388 Study Team.

J Infect Dis. 2003 Sep 1;188(5):625-34. Epub 2003 Aug 15. Erratum in: J Infect Dis. 2003 Oct 1;188(7):1083.

11.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

12.

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

Wintergerst U, Engelhorn C, Kurowski M, Hoffmann F, Notheis G, Belohradsky BH.

AIDS. 2000 Aug 18;14(12):1866-8. No abstract available.

PMID:
10985332
13.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140
14.

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.

Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.

PMID:
23043067
15.

Nelfinavir: an update on its use in HIV infection.

Bardsley-Elliot A, Plosker GL.

Drugs. 2000 Mar;59(3):581-620. Review.

PMID:
10776836
16.

Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ; ACTG A5093 Protocol Team.

Clin Pharmacol Ther. 2007 Feb;81(2):222-7. Epub 2006 Dec 27.

PMID:
17192768
17.

Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.

Herzmann C, Arastèh K, Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A, Cartee L, Otto MJ.

Antimicrob Agents Chemother. 2005 Jul;49(7):2828-33.

18.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
19.

Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.

Morse GD, Rosenkranz S, Para MF, Segal Y, Difrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC.

Antimicrob Agents Chemother. 2005 Aug;49(8):3373-81.

20.

Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis.

Gill MJ, Ostrop NJ, Fiske WD, Brennan JM.

AIDS. 2000 May 26;14(8):1062-4. No abstract available.

PMID:
10853991
Items per page

Supplemental Content

Write to the Help Desk